The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound - Kelm, Sörge; Gerlach, Judith; Brossmer, Reinhard; Danzer, Claus-Peter; Nitschke, Lars (Journal of experimental medicine, 2002)
Gesehen am 07.10.2016